Abbott Laboratories [ABT] took an upward turn with a change of 6.19%, trading at the price of $75.13 during the trading session on Wednesday. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 2.82 million shares changed hands being bought and sold, while Abbott Laboratories shares have an average trading volume of 7.30M shares for that time period. ABT monthly volatility recorded 7.16%, in the meanwhile having share price volatility for the week set at 9.20%. PS value for ABT stocks is 4.16 with PB recorded at 4.02.

Abbott Laboratories [NYSE:ABT]: Analyst Rating and Earnings

Pro stock market traders often keep their attention pointed at what top market analysts have to say regarding a potential equity investment. For Abbott Laboratories [ABT] currently, the latest-available mean analyst rating is for the fiscal quarter that will end in 12/30/2019. On average, stock market experts give ABT an Overweight rating. The average 12-month price forecast for this stock is $75.13, with the high estimate being $105.00, the low estimate being $95.00 and the median estimate amounting to $101.00. This is compared to its latest closing price of $70.75.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Abbott Laboratories [ABT] is sitting at 4.50. This is compared to 1 month ago, when its average rating was 4.46.

Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for 04/16/2020.

Fundamental Analysis of Abbott Laboratories [ABT]

Now let’s turn to look at profitability: with a current Operating Margin for Abbott Laboratories [ABT] sitting at 14.00% and its Gross Margin at 58.60%, this company’s Net Margin is now 11.60. These measurements indicate that Abbott Laboratories [ABT] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

Similarly, its Total Debt to Total Assets stands at 28.13.

What about valuation? This company’s Enterprise Value to EBITDA is 22.24 and its Total Debt to EBITDA Value is 2.39. The Enterprise Value to Sales for this firm is now 5.30. Abbott Laboratories [ABT] has a Price to Book Ratio of 4.92, a Price to Cash Flow Ratio of 25.21 and P/E Ratio of 36.44. These metrics suggest that this publicly-traded organization will not likely result in investment gains.

Abbott Laboratories [ABT] has 1.88B shares outstanding, amounting to a total market cap of 132.73B. Its stock price has been found in the range of 61.61 to 92.45. At its current price, it has moved down by -18.73% from its 52-week high, and it has moved up 21.94% from its 52-week low.

This stock’s Beta value is currently 0.74, which indicates that it is 9.20% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 47.26. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Abbott Laboratories [ABT] a Reliable Buy?

Shares of Abbott Laboratories [ABT], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.